Company intelligence / Profile preview
Medicenna Therapeutics
Toronto, Ontario, Canadamedicenna.com ↗
- Ownership
- Public · MDNA
- Development stage
- Phase 2
01
Overview
Medicenna’s lead asset MDNA11 has shown a single-agent response rate of ~29% in patients with checkpoint-resistant solid tumors. Bizaxofusp demonstrated compelling long-term survival benefit in recurrent glioblastoma patients and has received Fast Track and Orphan Drug designations from the FDA/EMA. The company continues to expand its clinical studies into Europe and plans to seek Breakthrough Therapy Designation for bizaxofusp based on recent data[6].
- Therapeutic areas
- OncologyImmunology
- Modalities
- Engineered cytokines (Superkines)Protein therapeutics (interleukins IL‑2, IL‑4, IL‑13 variants)Bifunctional immunotherapies
- Industry
- Biotech
02
Drug pipeline
20 assets19 more assets in the full pipeline.
Request access →03
Partnerships
Pembrolizumab combination trial with Merck’s KEYTRUDA® as part of ABILITY–1 study[6]RA Capital investment partnership.
04
Financials
- Market cap
- $0
- Total revenue
- $0
- Enterprise value
- $-25.7M
Beyond the preview
Go deeper on Medicenna Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Medicenna Therapeutics.